ANAB (AnaptysBio) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANAB AnaptysBio Inc ANAB
67 GF Score
Price $58.00
GF Value $59.79
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is AnaptysBio Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

ANAB
67GF Score
AnaptysBio Inc ANAB
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AnaptysBio (ANAB) Overvalued in 2026?

Based on GuruFocus' analysis, AnaptysBio stock appears to be undervalued. The current stock price of $58.00 is trading 3% below its estimated GF Value™ of $59.79. GuruFocus considers AnaptysBio to be Fairly Valued.

Key valuation signals for ANAB:

  • Interest Received:
  • GF Value™: $59.79 vs. price of $58.00 (3% below fair value)
  • GF Score™: 67/100 with 2 warning signs

No single metric tells the full story. See the ANAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AnaptysBio Business Description

Other Exchanges 0HFQ:UKAN6:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
67GF Score

Get the complete analysis for ANAB

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$58.00
Price
$59.79
GF Value